Salute e Benessere
Wearable Injectors Market worth US$18.91 billion by 2030 with 10.8% CAGR | MarketsandMarkets™
the spring-based technology segment leads the wearable injectors market due to its reliability, simplicity, and cost-effectiveness. It utilizes mechanical spring mechanisms for controlled drug delivery, making it ideal for large-volume biologics and viscous drugs in chronic conditions like cancer and diabetes. Its user-friendly design and minimal intervention make it suitable for self-administration at home, enhancing patient compliance and ensuring safe delivery without complex electronics. This adaptability reinforces the segment's strong position in the wearable injectors market.
the market is currently led by the autoimmune diseases segment, driven by the rising incidence of chronic conditions like rheumatoid arthritis and Crohn's disease, which necessitate ongoing biologic treatments. A strong pipeline of biologics and payer initiatives to lower in-clinic costs also enhance adoption. The diabetes management segment is also rapidly growing due to the increasing prevalence of diabetes and advancements in wearable injectors, especially hybrid closed-loop systems—known as artificial pancreas devices—that combine continuous glucose monitoring with automated insulin delivery. Notable developments in accessible insulin pumps, featuring touchscreen interfaces and integration with mobile apps, improve patient adherence. The rise in diabetes cases is influenced by factors like an aging population and changing lifestyle habits, further boosting market growth.
, in 2024, North America led the wearable injectors market, driven by significant healthcare spending in the US, which reached about USD 4.9 trillion in 2023. This spending facilitated the adoption of advanced technologies, supported by a robust healthcare infrastructure with numerous hospitals and outpatient facilities. Major US manufacturers like BD, West Pharmaceutical Services, and Insulet Corporation contribute to this market growth. Additionally, the rising prevalence of chronic diseases and an aging population further increase the demand for wearable injectors, solidifying North America's leadership in this sector.
The leading companies that produce wearable injector devices include Medtronic ( Ireland ), BD (US), West Pharmaceutical Services, Inc. (US), Tandem Diabetes Care, Inc. (US), and Insulet Corporation (US). These companies have established strong positions in the market through innovations in wearable design, delivery efficiency, and patient-centric features.
On the other hand, the top companies that offer wearable injector formulations are Amgen Inc. (US), AbbVie Inc. (US), United Therapeutics Corporation (US), Apellis Pharmaceuticals, Inc. (US), and Supernus Pharmaceuticals, Inc. (US). These companies have developed or formed partnerships to commercialize biologics and specialty drugs that are designed for subcutaneous self-administration through wearable platforms.
Medtronic is a medical technology company that provides innovative solutions for over 30 chronic diseases, including cardiovascular and diabetes conditions. It operates through four segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, offering wearable injectors in the latter. The company is recognized for its innovation and has a significant presence in the US, Europe , and Japan , with manufacturing and research facilities in multiple countries. The company has pursued both organic growth and strategic acquisitions. In April 2025 , it received FDA approval for the Simplera Sync sensor for use with the MiniMed 780G system, enhancing insulin delivery flexibility. In 2023, Medtronic acquired EOFlow Co. Ltd., which manufactures the EOPatch, a tubeless insulin delivery device, furthering its capabilities to assist individuals with diabetes.
AbbVie Inc. is a leading biopharmaceutical company focused on research and innovation in areas such as oncology, autoimmune diseases, virology, and neurology. The company offers drugs across various therapeutic segments, including its wearable injector Skyrizi for immunology. Operating in over 70 countries with 22 R&D facilities, AbbVie announced in 2024 that the FDA approved VYALEV as the first subcutaneous 24-hour infusion therapy for motor fluctuations in advanced Parkinson's disease. Additionally, AbbVie expanded its presence in Germany with a new research center, LUnA, investing approximately USD 172 million to create its second-largest R&D location globally.
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, , and . With a , we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/wearable-injectors-market-worth-us18-91-billion-by-2030-with-10-8-cagr--marketsandmarkets-302550589.html